Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Evaxion (NASDAQ:EVAX) will present new preclinical data on its off-the-shelf AML vaccine EVX-04 at the EHA 2026 Congress in Stockholm on June 13, 2026. The functional characterization data mark a step towards clinical testing, with a clinical trial application planned for the second half of 2026.
Evaxion (NASDAQ: EVAX) reported Q1 2026 results and a business update on May 7, 2026. Key points: AI-Immunology™ achieved 86% vaccine target recognition for EVX-01; phase 2 one-year extension completed with three-year data expected H2 2026; new polio vaccine designs from Gates Foundation collaboration; cash $18.4M; runway into H2 2027.
Evaxion (NASDAQ: EVAX) will release a business update and first quarter 2026 financial results on May 7, 2026, before Nasdaq opening. Management will host a conference call and webcast on the same day at 14:30 CET / 08:30 EST. Registration is required to obtain dial-in numbers and a PIN.
The webcast will open 15 minutes early and a recording will be posted on the company website shortly after the event. Contact: Mads Kronborg, Vice President, Investor Relations & Communication.
Evaxion (NASDAQ: EVAX) announced on April 27, 2026 that Birgitte Rønø, previously Chief Scientific Officer, has been promoted to a dual role as Chief Scientific Officer and Chief Operating Officer. The change follows an internal management review to align organisation structure to maximise external engagement with partners and investors. Management composition otherwise remains: Helen Tayton-Martin, CEO; Thomas Schmidt, CFO; Andreas Mattsson, Chief AI Officer. Contact: Mads Kronborg, VP Investor Relations.
Evaxion (NASDAQ: EVAX) reported phase 2 EVX-01 data showing 86% of vaccine targets triggered tumor-specific immune responses and durable two-year vaccine-specific responses.
The trial tested EVX-01 with KEYTRUDA in advanced melanoma, reported a 75% objective response rate, and will present detailed results at AACR on April 22, 2026.
Evaxion (NASDAQ: EVAX) reports new data showing its AI-Immunology™ platform can identify endogenous retrovirus (ERV)-derived antigens in glioblastoma and design vaccine candidates. Findings include bioinformatic ERV profiling, neoantigen detection in most patients, and experimental immunologic responses.
Data were generated with Duke University and will be presented at AACR on April 22, 2026 (Poster #6975).
Evaxion (NASDAQ: EVAX) held its Annual General Meeting on April 16, 2026 at its Copenhagen offices. The 2025 Annual Report was approved and the Board proposals passed. Four directors were re-elected and one new director, Jens Bitsch Nørhave, was elected. Minutes are available on the company website.
Evaxion (NASDAQ: EVAX) completed the one-year extension of its phase 2 trial of personalized cancer vaccine EVX-01, with the last patient visit on April 7, 2026.
First-two-year results showed a 75% Objective Response Rate (12/16), four complete responses, 92% still responding at two years, and high immunogenicity (81% neoantigen response). Three-year efficacy data are expected in the second half of 2026.
Evaxion (NASDAQ: EVAX) will present AI-driven polio vaccine design concepts and CMV program data at the World Vaccine Congress in Washington D.C., March 31–April 2, 2026. The company, in collaboration with the Gates Foundation, described hybrid capsid and de novo B-cell antigen approaches and will present EVX-V1 CMV antigen data on April 2, 2026.
Presentations aim to showcase AI-Immunology™ platform capabilities and early results supporting further development and potential collaborations.
Evaxion (NASDAQ: EVAX) has convened its Annual General Meeting for April 16, 2026 at 14:00 CET to be held at the company's offices in Hørsholm, Denmark. The agenda and meeting materials are available on the company's investor website, and investor contact details are provided for further questions.